Prothena (STU:0PT) Float Percentage Of Total Shares Outstanding: 83.37% (As of Jul. 12, 2026)


STU:0PT Prothena Corp PLC STU:0PT
74 GF Score
Price €8.13
GF Value €12.89
! 3 Warning Signs
View Full Analysis

What is Prothena Float Percentage Of Total Shares Outstanding?

Prothena STU:0PT -3.44% 74 Float Percentage Of Total Shares Outstanding is 83.37% as of Jul. 12, 2026. GuruFocus rates STU:0PT with a GF Score™ of 74/100 and a GF Value™ of €12.89. The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Prothena's float shares is 43.64 Mil. Prothena's total shares outstanding is 52.35 Mil. Prothena's float percentage of total shares outstanding is 83.37%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Prothena's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Prothena's Institutional Ownership is 41.07%.

STU:0PT
74GF Score
Prothena Corp PLC STU:0PT
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prothena Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Prothena's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=43.64/52.35
=83.37%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 83.37% mean?
Prothena (STU:0PT) has a Float Percentage Of Total Shares Outstanding of 83.37% as of Jul. 12, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Prothena and its competitors.
Is Prothena's Float Percentage Of Total Shares Outstanding too high?
Prothena's current Float Percentage Of Total Shares Outstanding is 83.37%. Overall, Prothena has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Prothena's Float Percentage Of Total Shares Outstanding compare to CTNM and ASMB?
Prothena's Float Percentage Of Total Shares Outstanding of 83.37% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Prothena and its competitors. Prothena's current Float Percentage Of Total Shares Outstanding is 83.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prothena stock overvalued right now?
Prothena (STU:0PT) has a current Float Percentage Of Total Shares Outstanding of 83.37%. The stock's GF Value™ is €12.89, compared to a current price of €8.13 — trading 36.9% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 83.37%. Prothena's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Prothena (STU:0PT), the current Float Percentage Of Total Shares Outstanding is 83.37% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prothena (STU:0PT) Overvalued in 2026?

Based on GuruFocus' analysis, Prothena stock appears to be undervalued. The current stock price of €8.13 is trading 36.9% below its estimated GF Value™ of €12.89.

Key valuation signals for STU:0PT:

  • Float Percentage Of Total Shares Outstanding: 83.37%
  • GF Value™: €12.89 vs. price of €8.13 (36.9% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the STU:0PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prothena Business Description

Other Exchanges PRTA:USA0Y3M:UK0PT:Germany
Address 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, Dublin, IRL, D02 VK60
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
74GF Score

Get the complete analysis for STU:0PT

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.13
Price
€12.89
GF Value